Reviva Pharmaceuticals is a late-stage pharmaceutical company developing therapies for central nervous system, inflammatory, and cardiometabolic diseases.
For the full year ended December 31, 2025, Reviva reported an earnings per share (EPS) equivalent to a net loss of $5.48 per share. The company’s consolidated statements of operations did not report any revenue for 2025. Overall, the company reported a net loss of approximately $19.9 million for the year.
During 2025, the company’s research and development expenses totaled roughly $11.7 million. By the end of 2025, Reviva held $14.4 million in cash and cash equivalents. A subsequent public equity offering in March 2026 raised $10.0 million in gross proceeds, extending their estimated cash runway into the first quarter of 2027.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.